Telix to Host Investor Day in New York City on June 11, 2025

Rhea-AI Summary

Telix Pharmaceuticals (ASX: TLX, NASDAQ: TLX) has announced an upcoming Investor Day scheduled for June 11, 2025, in New York City. The event will run from 8:30 AM to 12:00 PM ET and will focus on growth opportunities across Telix's commercial and clinical portfolio of precision medicine and therapeutic radiopharmaceuticals.

Key presenters will include CEO Dr. Christian Behrenbruch, CMO Dr. David N. Cade, CEO Therapeutics Richard Valeix, and CEO Precision Medicine Kevin Richardson. Key Opinion Leaders will also share insights on Telix's theranostic candidates. The event is exclusively for qualified institutional investors and analysts, with advance registration required via email.

MELBOURNE, Australia and INDIANAPOLIS, May 22, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”, “the Company”) today announces it will host an Investor Day on Wednesday, June 11, 2025, in person, in New York City, from 8:30am ET to 12.00pm ET.

Institutional investors, analysts and company guests are cordially invited to attend the session, which will focus on the growth opportunities across Telix’s commercial and clinical portfolio of precision medicine and therapeutic radiopharmaceuticals.

Members of the Telix leadership team will present at the event, including Managing Director and Group CEO, Dr. Christian Behrenbruch; Group Chief Medical Officer, Dr. David N. Cade; CEO Therapeutics, Mr. Richard Valeix and CEO Precision Medicine, Mr. Kevin Richardson.

Key Opinion Leaders will also provide their perspectives on the clinical utility and opportunity for Telix’s theranostic candidates.

Advance registration is required for in person attendance. Please RSVP by sending an email to annie.kasparian@telixpharma.com.

Note: This event is for qualified institutional investors and analysts.

About Telix Pharmaceuticals Limited

Telix is a biopharmaceutical company focused on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals and associated medical technologies. Telix is headquartered in Melbourne, Australia, with international operations in the United States, Brazil, Canada, Europe (Belgium and Switzerland), and Japan. Telix is developing a portfolio of clinical and commercial stage products that aims to address significant unmet medical needs in oncology and rare diseases. ARTMS, IsoTherapeutics, Lightpoint, Optimal Tracers and RLS are Telix Group companies. Telix is listed on the Australian Securities Exchange (ASX: TLX) and the Nasdaq Global Select Market (NASDAQ: TLX).

Visit www.telixpharma.com for further information about Telix, including details of the latest share price, ASX and SEC filings, investor and analyst presentations, news releases, event details and other publications that may be of interest. You can also follow Telix on LinkedIn, X and Facebook.

Telix Investor Relations

Ms. Kyahn Williamson
Telix Pharmaceuticals Limited
SVP Investor Relations and Corporate Communications
Email: kyahn.williamson@telixpharma.com

Telix Investor Relations (U.S.) 

Annie Kasparian 
Telix Pharmaceuticals Limited 
Director Investor Relations and Corporate Communications 
Email: annie.kasparian@telixpharma.com

Lisa Wilson 
In-Site Communications 
Email: lwilson@insitecony.com

Legal Notices

You should read this announcement together with our risk factors, as disclosed in our most recently filed reports with the Australian Securities Exchange (ASX), U.S. Securities and Exchange Commission (SEC), including our Annual Report on Form 20-F filed with the SEC, or on our website.

The information contained in this announcement is not intended to be an offer for subscription, invitation or recommendation with respect to securities of Telix Pharmaceuticals Limited (Telix) in any jurisdiction, including the United States. The information and opinions contained in this announcement are subject to change without notification. To the maximum extent permitted by law, Telix disclaims any obligation or undertaking to update or revise any information or opinions contained in this announcement, including any forward-looking statements (as referred to below), whether as a result of new information, future developments, a change in expectations or assumptions, or otherwise. No representation or warranty, express or implied, is made in relation to the accuracy or completeness of the information contained or opinions expressed in the course of this announcement.

This announcement may contain forward-looking statements, including within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, that relate to anticipated future events, financial performance, plans, strategies or business developments. Forward-looking statements can generally be identified by the use of words such as “may”, “expect”, “intend”, “plan”, “estimate”, “anticipate”, “believe”, “outlook”, “forecast” and “guidance”, or the negative of these words or other similar terms or expressions. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Forward-looking statements are based on Telix’s good-faith assumptions as to the financial, market, regulatory and other risks and considerations that exist and affect Telix’s business and operations in the future and there can be no assurance that any of the assumptions will prove to be correct. In the context of Telix’s business, forward-looking statements may include, but are not limited to, statements about: the initiation, timing, progress and results of Telix’s preclinical and clinical trials, and Telix’s research and development programs; Telix’s ability to advance product candidates into, enrol and successfully complete, clinical studies, including multi-national clinical trials; the timing or likelihood of regulatory filings and approvals for Telix’s product candidates, manufacturing activities and product marketing activities; Telix’s sales, marketing and distribution and manufacturing capabilities and strategies; the commercialization of Telix’s product candidates, if or when they have been approved; Telix’s ability to obtain an adequate supply of raw materials at reasonable costs for its products and product candidates; estimates of Telix’s expenses, future revenues and capital requirements; Telix’s financial performance; developments relating to Telix’s competitors and industry; the anticipated impact of U.S. and foreign tariffs and other macroeconomic conditions on Telix’s business; and the pricing and reimbursement of Telix’s product candidates, if and after they have been approved. Telix’s actual results, performance or achievements may be materially different from those which may be expressed or implied by such statements, and the differences may be adverse. Accordingly, you should not place undue reliance on these forward-looking statements.

©2025 Telix Pharmaceuticals Limited. Telix Pharmaceuticals®, Telix Group company, and Telix product names and logos are trademarks of Telix Pharmaceuticals Limited and its affiliates – all rights reserved. Trademark registration status may vary from country to country.

FAQ

When and where is Telix Pharmaceuticals (TLX) hosting its 2025 Investor Day?

Telix Pharmaceuticals is hosting its Investor Day on Wednesday, June 11, 2025, in New York City from 8:30 AM to 12:00 PM ET.

Who are the key executives presenting at Telix's 2025 Investor Day?

Key presenters include CEO Dr. Christian Behrenbruch, CMO Dr. David N. Cade, CEO Therapeutics Richard Valeix, and CEO Precision Medicine Kevin Richardson.

What topics will be covered at the TLX Investor Day 2025?

The event will focus on growth opportunities across Telix's commercial and clinical portfolio of precision medicine and therapeutic radiopharmaceuticals.

How can investors register for Telix's 2025 Investor Day?

Qualified institutional investors and analysts can register by sending an email to annie.kasparian@telixpharma.com.